Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 36, 2008, Pages 13520-13525

  Lenz, Georg ^a   Wright, George W ^a   Emre, N C Tolga ^a   Kohlhammer, Holger ^a   Dave, Sandeep S ^a   Davis, R Eric ^a   Carty, Shannon ^a   Lam, Lloyd T ^a   Shaffer, A L ^a   Xiao, Wenming ^b   Powell, John ^b   Rosenwald, Andreas ^c   Ott, German ^c,d   Muller Hermelink, Hans Konrad ^c   Gascoyne, Randy D ^e   Connors, Joseph M ^e   Campo, Elias ^f   Jaffe, Elaine S ^a   Delabie, Jan ^g   Smeland, Erlend B ^g   Rimsza, Lisa M ^h   Fisher, Richard I ^i,j   Weisenburger, Dennis D ^k   Chan, Wing C ^k   Staudt, Louis M ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d ROBERT BOSCH HOSPITAL   (Germany)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

^f UNIVERSITY OF BARCELONA   (Spain)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

ⁱ Southwest Oncology Group   (United States)

^j UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^k UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

more..

Author keywords

Comparative genomic hybridization; Gene expression profiling; Oncogenes; Tumor suppressor genes

Indexed keywords

MICRORNA; TRANSCRIPTION FACTOR ETS;

AMPLICON; ARF GENE; ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; CANCER INHIBITION; CHROMOSOME 19; CHROMOSOME ABERRATION; CYTOTOXICITY; FOXP1 GENE; GENE AMPLIFICATION; GENE CLUSTER; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE LOCUS; GENETIC ANALYSIS; GENOME; GERMINAL CENTER; HUMAN; HUMAN TISSUE; INK4A GENE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOMA CELL; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PTEN GENE; RNA INTERFERENCE; SPIB GENE; TUMOR BIOPSY; TUMOR SUPPRESSOR GENE;

BIOPSY; CELL SURVIVAL; CHROMOSOME ABERRATIONS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; ONCOGENE PROTEINS; PROGNOSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 51649111684     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0804295105     Document Type: Article

References (33)

1. The Non-Hodgkin's Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918.
2. Coiffier B (2001) Diffuse large cell lymphoma. Curr Opin Oncol 13:325-334.
3. Alizadeh AA, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511.
4. Rosenwald A, et al. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947.
5. Wright G, et al. (2003) A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 100:9991-9996.
6. Rosenwald A, et al. (2003) Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198:851-862.
7. Savage KJ, et al. (2003) The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102:3871-3879.
8. Staudt LM, Dave S (2005) The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol 87:163-208.
9. Bea S, et al. (2005) Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 106:3183-3190.
10. Tagawa H, et al. (2005) Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood 106:1770-1777.
11. Chen W, et al. (2006) Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas. Blood 107:2477-2485.
12. Aguirre AJ, et al. (2004) High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci USA 101:9067-9072.
13. Tonon G, et al. (2005) High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci USA 102:9625-9630.
14. Redon R, et al. (2006) Global variation in copy number in the human genome. Nature 444:444-454.
15. Shaffer AL, Rosenwald A, Staudt LM (2002) Lymphoid malignancies: The dark side of B-cell differentiation. Nat Rev Immunol 2:920-932.
16. Wlodarska I, et al. (2005) FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia 19:1299-1305.
17. Streubel B, Vinatzer U, Lamprecht A, Raderer M, Chott A (2005) t(3;14)(p14.1;q32) Involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 19:652-658.
18. Motoyama M, Yamazaki S, Eto-Kimura A, Takeshige K, Muta T (2005) Positive and negative regulation of nuclear factor-kappaB-mediated transcription by IkappaB-zeta, an inducible nuclear protein. J Biol Chem 280:7444-7451.
19. Davis RE, Brown KD, Siebenlist U, Staudt LM (2001) Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194:1861-1874.
20. Lam LT, et al. (2005) Small molecule inhibitors of IkB-kinase are selectively toxic for subgroups of diffuse large B cell lymphoma defined by gene expression profiling. Clin Cancer Res 11:28-40.
21. Ngo VN, et al. (2006) A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441:106-110.
22. Lam LT, et al. (2008) Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 111:3701-3713.
23. Lenz G, et al. (2007) Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med 204:633-643.
24. Su GH, et al. (1997) Defective B cell receptor-mediated responses in mice lacking the Ets protein, Spi-B. EMBO J 16:7118-7129.
25. Ota A, et al. (2004) Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 64:3087-3095.
26. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT (2005) c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435:839-843.
27. Siebert R, et al. (1998) Deletions in the long arm of chromosome 10 in lymphomas with t(14;18): A pathogenetic role of the tumor suppressor genes PTEN/MMAC1 and MXI1? Blood 92:4487-4489.
28. Soliman MA, Riabowol K (2007) After a decade of study-ING, a PHD for a versatile family of proteins. Trends Biochem Sci 32:509-519.
29. Joos S, et al. (2000) Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 60:549-552.
30. Thomas RK, et al. (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39:347-351.
31. Hummel M, et al. (2006) A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354:2419-2430.
32. Haralambieva E, et al. (2006) Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation. Leukemia 20:1300-1303.
33. Lenz G, et al. (2008) Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319:1676-1679.